Nabriva Extends Exclusive Agreement to Promote and Distribute Sivextro® (Tedizolid Phosphate) in the U.S. Through the End of 2026
Nabriva has been marketing and distributing SIVEXTRO in the United States and certain of its territories as part of an exclusive agreement executed in July 2020 with Merck. Under the initial term of the agreement, Nabriva was solely responsible for marketing, sales, and distribution of SIVEXTRO in the United States through December 31, 2023. The amendment extends the agreement to December 31, 2026. The term of the agreement can be further extended by an additional three-year period, subject to mutual agreement.